Rimke O.
- Country
- The Netherlands
- Department
- Hematology Department
Research Overview
- A phase I/II open label, multicenter study evaluating the feasibility, safety and efficacy of point-of-care manufactured antiBCMA CAR T cells (GLPG5301; BCMACP03) in subjects with relapsed/refractory Multiple Myeloma (RRMM)
- Evaluation of Epcoritamab in Combination with Chemotherapeutic Agents in B-cell Non-Hodgkin Lymphoma: A Phase 1b/2 Open-Label Study
- Phase 1/2 Open-Label Dose-Escalation Study of Epcoritamab in Relapsed, Progressive, or Refractory B-Cell Lymphoma with Anakinra and Drug Combination
Data & Insights
Has run more than one trial at 24 of 69 partner sites.
Specializations
Hematologic Malignancies
This investigator specializes in various forms of blood cancers, with particular focus on multiple myeloma and lymphoid malignancies. Their research encompasses both established and innovative therapeutic approaches.
- Multiple Myeloma Treatment Development
- B-cell Non-Hodgkin Lymphoma Management
- Novel Therapeutic Combinations
Notable involvement in evaluating emerging treatments including targeted antibody therapies and CAR T-cell approaches.
Leukemia Research
Focused on advancing treatment options for various types of leukemia, including acute myeloid leukemia and chronic lymphocytic leukemia.
- Chronic Myeloid Leukemia Treatment Optimization
- Novel AML Therapy Combinations
- CLL Treatment Strategies
Expertise in developing personalized treatment approaches and dose optimization strategies.
Rare Blood Disorders
Investigates uncommon blood conditions, including myelodysplastic syndrome and monoclonal gammopathies.
- MGUS-Related Disorders
- Polyneuropathy Associated Conditions
- Innovative Treatment Protocols
Specializes in developing treatment strategies for complex and rare hematological conditions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.